第一作者机构:[1]Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea;
推荐引用方式(GB/T 7714):
Park Keunchil,Tan Eng Huat,Zhang Li,et al.First-Line Afatinib versus Gefitinib in EGFRm plus Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7[J].JOURNAL OF THORACIC ONCOLOGY.2017,12(1):S335-S336.
APA:
Park, Keunchil,Tan, Eng Huat,Zhang, Li,Hirsh, Vera,O'Byrne, Ken...&Paz-Ares, Luis.(2017).First-Line Afatinib versus Gefitinib in EGFRm plus Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7.JOURNAL OF THORACIC ONCOLOGY,12,(1)
MLA:
Park, Keunchil,et al."First-Line Afatinib versus Gefitinib in EGFRm plus Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7".JOURNAL OF THORACIC ONCOLOGY 12..1(2017):S335-S336